| Literature DB >> 30309671 |
Tom Baladi1, Jessy Aziz2, Florent Dufour3, Valentina Abet2, Véronique Stoven4, François Radvanyi3, Florent Poyer2, Ting-Di Wu2, Jean-Luc Guerquin-Kern2, Isabelle Bernard-Pierrot3, Sergio Marco Garrido2, Sandrine Piguel5.
Abstract
The TAM kinase family arises as a new effective and attractive therapeutic target for cancer therapy, autoimmune and viral diseases. A series of 2,6-disubstituted imidazo[4,5-b]pyridines were designed, synthesized and identified as highly potent TAM inhibitors. Despite remarkable structural similarities within the TAM family, compounds 28 and 25 demonstrated high activity and selectivity in vitro against AXL and MER, with IC50 value of 0.77 nM and 9 nM respectively and a 120- to 900-fold selectivity. We also observed an unexpected nuclear localization for compound 10Bb, thanks to nanoSIMS technology, which could be correlated to the absence of cytotoxicity on three different cancer cell lines being sensitive to TAM inhibition.Entities:
Keywords: AXL; Imidazopyridines; Kinase inhibitors; MER; NanoSIMS imaging; TYRO3
Mesh:
Substances:
Year: 2018 PMID: 30309671 DOI: 10.1016/j.bmc.2018.09.031
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641